Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Montse Tuset Creus"'
Publikováno v:
Farmacia Hospitalaria, Vol 44, Iss Supl 1, Pp 28-31 (2020)
During the pandemic caused by the SARS-CoV-2 virus, pharmacy services have had to adapt their service portfolio, and yet ensure efficient, equitable and quality pharmaceutical care. Given the limited scientific evidence available, most drugs have bee
Externí odkaz:
https://doaj.org/article/c282e1667f194ef8ba27016be78d5c9b
Autor:
Mio Sakuma, Montse Tuset Creus, Takeshi Morimoto, Eveline B. Boeker, Marcel G. W. Dijkgraaf, Monica de Boer, Marja A. Boermeester, Kim Ram, Joanna E. Klopotowska, Ana López de Andrés
Publikováno v:
British Journal of Clinical Pharmacology. 79:548-557
AIM The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This individual patient data meta-analysis (IPDMA) identifies patient characteristics and types of medication most associated with patients experiencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::898080500107e69123bf156dbec18770
https://doi.org/10.1111/bcp.12504
https://doi.org/10.1111/bcp.12504
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica. 26:23-28
Raltegravir is the first integrase inhibitor approved for the treatment of HIV-1 infection in pretreated adults with evidence of viral replication despite receiving antiretroviral therapy. Raltegravir is administered orally at a dose of 400 mg every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43a0d5295e927a5fedb7176f0f0122c4
https://doi.org/10.1016/s0213-005x(08)76569-8
https://doi.org/10.1016/s0213-005x(08)76569-8
Autor:
Esteban Ribera Pascuet, Montse Tuset Creus, F Galo Peralta Fernández, Ismael Escobar Rodríguez, L Fernando López Cortés
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica. 24:19-28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1401b18aa284a948840faba98b509a84
https://doi.org/10.1157/13096046
https://doi.org/10.1157/13096046
Autor:
Eveline B, Boeker, Kim, Ram, Joanna E, Klopotowska, Monica, de Boer, Montse Tuset, Creus, Ana L, de Andrés, Mio, Sakuma, Takeshi, Morimoto, Marja A, Boermeester, Marcel G W, Dijkgraaf
Publikováno v:
British journal of clinical pharmacology. 79(4)
The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This individual patient data meta-analysis (IPDMA) identifies patient characteristics and types of medication most associated with patients experiencing ADE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::92fcf1364ae538553c9ea9bb05831543
https://pubmed.ncbi.nlm.nih.gov/25199645
https://pubmed.ncbi.nlm.nih.gov/25199645
Publikováno v:
Enfermedades infecciosas y microbiologia clinica. 26
Raltegravir is the first integrase inhibitor approved for the treatment of HIV-1 infection in pretreated adults with evidence of viral replication despite receiving antiretroviral therapy. Raltegravir is administered orally at a dose of 400 mg every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b989355fbd3c0183d3c5d671680c757b
https://pubmed.ncbi.nlm.nih.gov/19572422
https://pubmed.ncbi.nlm.nih.gov/19572422
Publikováno v:
Medicina Clínica. 125:438-439
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51775a5392478872a564b7b8fe34764
https://doi.org/10.1157/13079391
https://doi.org/10.1157/13079391
Publikováno v:
Medicina Clínica. 127:237
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::365763086f4d1ae683207ab9e5284cf7
https://doi.org/10.1157/13091019
https://doi.org/10.1157/13091019